1. Home
  2. BAK vs CDNA Comparison

BAK vs CDNA Comparison

Compare BAK & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$3.10

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.13

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAK
CDNA
Founded
1972
1998
Country
Brazil
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
BAK
CDNA
Price
$3.10
$20.13
Analyst Decision
Hold
Buy
Analyst Count
2
7
Target Price
$4.40
$26.67
AVG Volume (30 Days)
1.1M
751.3K
Earning Date
02-26-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.22
Revenue
$13,841,708,237.00
$357,998,000.00
Revenue This Year
N/A
$14.47
Revenue Next Year
$7.81
$11.35
P/E Ratio
N/A
$16.47
Revenue Growth
N/A
14.46
52 Week Low
$2.32
$10.96
52 Week High
$5.10
$25.55

Technical Indicators

Market Signals
Indicator
BAK
CDNA
Relative Strength Index (RSI) 54.60 55.38
Support Level $3.05 $16.94
Resistance Level $3.37 $21.20
Average True Range (ATR) 0.13 1.07
MACD 0.03 0.06
Stochastic Oscillator 51.38 71.21

Price Performance

Historical Comparison
BAK
CDNA

About BAK Braskem SA ADR

Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: